Search Results - "CRATER, Glenn D"

Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow by Ohar, Jill A., Mahler, Donald A., Davis, Gabrielle N., Lombardi, David A., Moran, Edmund J., Crater, Glenn D.

“…Introduction. Many patients with chronic obstructive pulmonary disease (COPD) may derive inadequate benefit from dry powder inhalers (DPIs) because of…”
Get full text

Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial by Kelleher, Dennis L, Mehta, Rashmi S, Jean-Francois, Bernadette M, Preece, Andrew F, Blowers, James, Crater, Glenn D, Thomas, Paul

“…Umeclidinium bromide (GSK573719; UMEC), a new long-acting muscarinic receptor antagonist (LAMA), is in development with vilanterol (GW642444; VI), a selective…”
Get full text

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis by Donohue, James F, Kerwin, Edward, Barnes, Chris N, Moran, Edmund J, Haumann, Brett, Crater, Glenn D

“…Revefenacin, a once-daily, long-acting muscarinic antagonist delivered via standard jet nebulizer, increased trough forced expiratory volume in 1 s (FEV ) in…”
Get full text

Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol by BADESCH, David B, MCGOON, Michael D, BARST, Robin J, TAPSON, Victor F, RUBIN, Lewis J, WIGLEY, Fredrick M, KRAL, Kenneth M, RAPHIOU, Ibrahim H, CRATER, Glenn D

“…Objective. Pulmonary arterial hypertension (PAH) remains challenging to treat, especially in association with scleroderma. We examined survival rates among…”
Get full text

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials by Sethi, Sanjay, Donohue, James F., Ferguson, Gary T., Barnes, Chris N., Crater, Glenn D.

“…Background: Combinations of a long-acting muscarinic receptor antagonist (LAMA), long-acting β-agonist (LABA), and inhaled corticosteroid (ICS) are used for…”
Get full text

431-P: Effects of CB1 Antagonist INV-202 in Patients with Metabolic Syndrome—A Randomized, Placebo-Controlled, Double-Blind Phase 1B Study by CRATER, GLENN D., RAVENELLE, FRANCOIS, LALONDE, KARINE, DESPRÉS, JEAN-PIERRE

“…Cannabinoid blockers have been successful for the treatment of obesity. However, due to CNS side effects drug development programs were halted. We present data…”
Get full text

Prevalence of Airway Obstruction Assessed by Lung Function Questionnaire by Mintz, Matthew L., MD, Yawn, Barbara P., MD, MSc, Mannino, David M., MD, Donohue, James F., MD, Hanania, Nicola A., MD, Grellet, Catherine A., MD, Gilsenan, Alicia W., PhD, McLeod, Lori D., PhD, Dalal, Anand A., PhD, Raphiou, Ibrahim H., PhD, Prillaman, Barbara A., MS, Crater, Glenn D., MD, Cicale, Michael J., MD, Mapel, Douglas W., MD

“…OBJECTIVE To estimate the prevalence of unidentified chronic obstructive pulmonary disease (COPD) and determine the screening accuracy of the Lung Function…”
Get full text

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 by Singh, Dave, Bogus, Maxim, Moskalenko, Valentyn, Lord, Robert, Moran, Edmund J, Crater, Glenn D, Bourdet, David L, Pfeifer, Nathan D, Woo, Jacky, Kaufman, Elad, Lombardi, David A, Weng, Emily Y, Nguyen, Tuan, Woodcock, Ashley, Haumann, Brett, Saggar, Rajeev

“…Severe coronavirus disease 2019 (COVID-19) is characterised by pneumonia with excessive systemic inflammation, referred to as a “cytokine storm” [1–3]…”
Get full text

Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD by Dalal, Anand A, Shah, Manan B, D'Souza, Anna O, Lunacsek, Orsolya E, Nagar, Saurabh P, Crater, Glenn D

“…There are limited data describing patients with moderate COPD exacerbations and evaluating comparative effectiveness of maintenance treatments in this patient…”
Get full text

Effects of CB1R inverse agonist, INV‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study by Crater, Glenn D., Lalonde, Karine, Ravenelle, François, Harvey, Michael, Després, Jean‐Pierre

“…Aims To evaluate the clinical safety, tolerability, and pharmacokinetic and pharmacodynamic profile of the novel cannabinoid receptor‐1 (CB1R) inverse agonist,…”
Get full text

Peak Inspiratory Flows: Defining Repeatability Limits and a Predictive Equation for Different Inhalers by Barnes, Chris N, Mahler, Donald A, Ohar, Jill A, Lombardi, David A, Crater, Glenn D

“…Peak inspiratory flow (PIF) has been proposed as a measure to assess a patient's ability to use dry powder inhalers (DPIs). However, robust quality criteria to…”
Get full text

Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease by Crater, Glenn D., Johnson, Karmon, Ward, Jonathan, Backer, Jan De

“…Background: Data for bronchodilator deposition via nebulizers and dry powder inhalers (DPIs) in the respiratory tract of patients with chronic obstructive…”
Get full text

Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate by Mahler, Donald A, Ohar, Jill A, Barnes, Chris N, Moran, Edmund J, Pendyala, Srikanth, Crater, Glenn D

“…Patients with chronic obstructive pulmonary disease (COPD) and suboptimal peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers…”
Get full text

Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD by Hanania, Nicola A, Crater, Glenn D, Morris, Andrea N, Emmett, Amanda H, O’Dell, Dianne M, Niewoehner, Dennis E

“…Summary Background Combining maintenance medications with different mechanisms of action may improve outcomes in COPD. In this study we evaluated the efficacy…”
Get full text

Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study by Siler, Thomas M, Moran, Edmund J, Barnes, Chris N, Crater, Glenn D

“…Although no nebulized, dual mechanism, long-acting bronchodilator is currently marketed, with the approval of once-daily long-acting muscarinic antagonist…”
Get full text

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation by Ohar, Jill A, Crater, Glenn D, Emmett, Amanda, Ferro, Thomas J, Morris, Andrea N, Raphiou, Ibrahim, Sriram, Peruvemba S, Dransfield, Mark T

“…Inhaled long-acting beta2 agonists used alone and in combination with an inhaled corticosteroid reduce the risk of exacerbations in patients with stable COPD…”
Get full text

Levalbuterol vs racemic albuterol: science or drug company propaganda? by Crater, Jr, Glenn D

Get more information

Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD by Maltais, François, Mahler, Donald A, Pepin, Véronique, Nadreau, Eric, Crater, Glenn D, Morris, Andrea N, Emmett, Amanda H, Ferro, Thomas J

Get full text

Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD by Dransfield, Mark T, Cockcroft, John R, Townsend, Raymond R, Coxson, Harvey O, Sharma, Sanjay S, Rubin, David B, Emmett, Amanda H, Cicale, Michael J, Crater, Glenn D, Martinez, Fernando J

“…Summary Background COPD is associated with increased arterial stiffness which may in part explain the cardiovascular morbidity observed in the disease. A…”
Get full text

Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy by Dalal, Anand A, Shah, Manan, D’Souza, Anna O, Crater, Glenn D

“…Summary Objective To determine clinical and economic outcomes following COPD-related hospitalization/emergency department (ED) care in patients receiving COPD…”
Get full text